Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
J Invest Dermatol ; 127(7): 1622-31, 2007 Jul.
Article in English | MEDLINE | ID: mdl-17380110

ABSTRACT

Studies performed to discover genes overexpressed in inflammatory diseases identified dermokine as being upregulated in such disease conditions. Dermokine is a gene that was first observed as expressed in the differentiated layers of skin. Its two major isoforms, alpha and beta, are transcribed from different promoters of the same locus, with the alpha isoform representing the C terminus of the beta isoform. Recently, additional transcript variants have been identified. Extensive in silico analysis and reverse transcriptase (RT)-PCR cloning has confirmed the existence of these variants in human cells and tissues, identified a new human isoform as well as the gamma isoform in mouse. Recombinant expression and analysis of the C-terminal truncated isoform indicate that the molecule is O-linked glycosylated and forms multimers in solution. In situ hybridization and immunohistochemistry has shown that the gene is differentially expressed in various cells and tissues, other than the skin. These results show that the dermokine gene is expressed in epithelial tissues other than the skin and this expression is transcriptionally and posttranscriptionally complex.


Subject(s)
DNA, Recombinant , Epithelial Cells/metabolism , Proteins/genetics , Proteins/metabolism , Amino Acid Sequence , Animals , Base Sequence , Cell Line, Tumor , Epithelial Cells/cytology , Exons/genetics , Gene Expression Regulation , Gene Expression Regulation, Neoplastic , Humans , Intercellular Signaling Peptides and Proteins , Keratinocytes/cytology , Keratinocytes/metabolism , Keratinocytes/pathology , Mice , Mice, Inbred C57BL , Molecular Sequence Data , Protein Isoforms/genetics , Protein Isoforms/metabolism , Protein Processing, Post-Translational , Transcription, Genetic
2.
Physiol Genomics ; 26(2): 125-33, 2006 Jul 12.
Article in English | MEDLINE | ID: mdl-16554548

ABSTRACT

To gain global pathway perspective of ex vivo viral infection models using human peripheral blood mononuclear cells (PBMCs), we conducted expression analysis on PBMCs of healthy donors. RNA samples were collected at 3 and 24 h after PBMCs were challenged with the Toll-like receptor-3 (TLR3) agonist polyinosinic acid-polycytidylic acid [poly(I:C)] and analyzed by internally developed cDNA microarrays and TaqMan PCR. Our results demonstrate that poly(I:C) challenge can elicit certain gene expression changes, similar to acute viral infection. Hierarchical clustering revealed distinct immediate early, early-to-late, and late gene regulation patterns. The early responses were innate immune responses that involve TLR3, the NF-kappaB-dependent pathway, and the IFN-stimulated pathway, whereas the late responses were mostly cell-mediated immune response that involve activation of cell adhesion, cell mobility, and phagocytosis. Overall, our results expanded the utilities of this ex vivo model, which could be used to screen molecules that can modulate viral stress-induced inflammation, in particular those mediated via TLRs.


Subject(s)
Gene Expression Profiling/methods , Gene Expression Regulation , Interferon Inducers/pharmacology , Leukocytes, Mononuclear/metabolism , Poly I-C/pharmacology , Cluster Analysis , Humans , Inflammation , Interferons/metabolism , Models, Biological , NF-kappa B/metabolism , Oligonucleotide Array Sequence Analysis , Phagocytosis , Toll-Like Receptor 3/metabolism
3.
Mini Rev Med Chem ; 3(3): 193-204, 2003 May.
Article in English | MEDLINE | ID: mdl-12570835

ABSTRACT

1alpha, 25-dihydroxyvitamin D3 [1,25 (OH)(2)D(3)], the active metabolite of vitamin D3, is known for the maintenance of normal skeleton architecture and mineral homeostasis. Apart form these traditional calcemic actions, 1,25 (OH)(3)D(1) and its synthetic analogs are increasingly recognized for their potent anti-proliferative, prodifferentiative and immunomodulatory activities. The calcemic and non-calcemic actions of 1,25 (OH)(2)D(3) and its synthetic analogs are mediated through vitamin D receptor (VDR), which belongs to the superfamily of steroid/thyroid hormone nuclear receptors. Physiological and pharmacological actions of 1,25 (OH)(2)D(3) in various systems, along with the detection of VDR in target cells, have indicated potential applications of VDR ligands in inflammation, dermatological indications, osteoporosis, cancers and autoimmune diseases. VDR ligands have shown therapeutic potential in limited clinical trials as well as in animal models of these diseases. As a result, a VDR ligand, calcipotriol is in clinic for psoriasis and another, OCT, [2-oxa-1,25 (OH)(2)D(3)] is being developed as a topical agent for the same indication. Further, 1alpha,-hydroxyvitamin D3 (alphacalcidol), a prodrug of 1,25 (OH)(2)D(3) is in clinic and a synthetic VDR ligand, ED-71, is under consideration for approval in Japan for the treatment of osteoporosis. Interestingly, VDR ligands have shown not only preventive but also potent therapeutic anabolic activities in animal models of osteoporosis. However, the wide spread use of VDR ligands in above-mentioned indications is hampered by their major side effect, namely hypercalcemia. In view of this associated toxicity, synthetic VDR ligands with reduced calcemic potential have been synthesized with the ultimate aim of improving their therapeutic efficacy. This review presents recent advances in VDR biology, novel VDR ligands and therapeutic applications of VDR ligands.


Subject(s)
Drug Design , Receptors, Calcitriol/metabolism , Vitamin D/therapeutic use , Autoimmune Diseases/drug therapy , Humans , Hyperparathyroidism, Secondary/drug therapy , Neoplasms/drug therapy , Osteoporosis/drug therapy , Psoriasis/drug therapy , Transcriptional Activation , Vitamin D/analogs & derivatives , Vitamin D/chemistry , Vitamin D/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...